Barchart on MSN2d
Are Wall Street Analysts Predicting Cardinal Health Stock Will Climb or Sink?
Dublin, Ohio-based Cardinal Health, Inc. (CAH) manufactures and distributes pharmaceuticals, medical & laboratory products, ...
With 88% ownership in Cardinal Health, Inc. (NYSE:CAH), institutional investors have a lot riding on the business
Key Insights Given the large stake in the stock by institutions, Cardinal Health's stock price might be vulnerable ...
Zacks Investment Research on MSN12d
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the ...
Fierce Pharma1d
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Cardinal Health Inc (CAH) Q2 2025 Earnings Call Highlights: Strong Pharma Growth Amid Revenue ...
Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...
Cardinal Health raised to buy by Jefferies
Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.
Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings
Wells Fargo analyst Stephen Baxter maintained Cardinal Health with an Equal-Weight and raised the price target from $135 to ...
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...
Nasdaq12d
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the Zacks Consensus Estimate of $1.75 by 10.3%. The bottom line also improved 2 ...